NASDAQ: TOIOncology Institute Inc Stock
$0.40+0.03 (+8.11%)
Updated Jan 15, 2025
TOI Price
$0.40
Fair Value Price
N/A
Market Cap
$30.22M
52 Week Low
$0.13
52 Week High
$2.45
P/E
-0.51x
P/B
1.95x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$378.93M
Earnings
-$55.04M
Gross Margin
14.2%
Operating Margin
-13.27%
Profit Margin
-14.5%
Debt to Equity
10.57
Operating Cash Flow
-$35M
Beta
0.5
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TOI Overview
The Oncology Institute Incorporated is an oncology company that provides physician services, in-house infusion and dispensary services, clinical trial services, radiation treatment services, outpatient stem cell transplants and transfusions programs, and patient support. The company also manages clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. through 67 clinics. The Oncology Institute was founded in 2007 and is based in Cerritos, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TOI's potential to beat the market
- TOI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
TOI
RankedUnranked of 44
RankedUnranked of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.00 | A | |
| $98.66 | A | |
| $5.94 | A |
Be the first to know about important TOI news, forecast changes, insider trades & much more!
TOI News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TOI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TOI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TOI is good value based on its book value relative to its share price (1.95x), compared to the US Medical Care Facilities industry average (4.34x)
P/B vs Industry Valuation
TOI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TOI due diligence checks available for Premium users.
Valuation
TOI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
12.65x
Market
30.62x
TOI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.95x
Industry
4.34x
TOI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TOI's financial health
Profit margin
Revenue
$99.9M
Net Income
-$16.1M
Profit Margin
-16.1%
TOI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TOI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$179.2M
Liabilities
$163.7M
Debt to equity
10.57
TOI's short-term assets ($116.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TOI's long-term liabilities ($116.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TOI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$819.0k
Investing
$10.4M
Financing
-$243.0k
TOI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TOI vs Medical Care Facility Stocks
Oncology Institute Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.